Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
Guardant Health (GH) was ordered to pay $245.2M for patent infringement, with a 6% royalty on US sales of 11 products until 2033. The company plans to appeal, noting current versions of Reveal and Shield are excluded. The judgment includes $83.4M in damages, $19.5M in supplemental damages, $119.4M in royalties, and $22.9M in interest.
How this was made
The 30-second read
Why it matters
The judgment introduces a sizable financial burden and ongoing royalty obligations, likely weighing on Guardant's valuation and prompting a sell‑off.
Market read
A major legal liability for a biotech firm can influence investor sentiment across the sector and raise awareness of IP risk management.
What to watch
Guardant's cash position and potential insurance coverage for legal liabilities may cushion the impact.
Background
Guardant Health faced a US court judgment of over $245M for willful infringement of DNA‑sequencing patents, with a 6% royalty on 11 products until 2033, while newer versions of two key tests are excluded.
Ticker impact
Guardant Health was ordered to pay a $245.2M judgment and a 6% royalty on US sales of 11 products until 2033.
expected decline of 5-10% over the next few weeks
The judgment amount is material and the royalty applies to a majority of past revenue; even with product exclusions, investors will react to the new liability.
Market effects
Liquid biopsy and cancer‑testing sector may see heightened scrutiny of IP risks.
U.S. biotech stocks could experience short‑term pressure.
Limited to companies with similar DNA‑sequencing patents.
Counterpoint
The appeal process could reduce the judgment, and newer product versions are excluded, limiting long‑term damage.
Key entities
- CompanyGuardant Health, Inc.
U.S. liquid biopsy and cancer‑testing firm (ticker GH).
- CompanyTwinStrand Biosciences
Patent holder asserting DNA‑sequencing patents.
- InstitutionUniversity of Washington
Co‑owner of the asserted patents.
